What Is Sweet Spot Dose Zepbound? Understanding Individual Response and Optimal Titration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The sweet spot dose for Zepbound (tirzepatide) is the lowest dose that produces your target weight loss (typically 1-2 pounds per week) with tolerable side effects, not a universal milligram number
• Clinical trial data shows most patients reach optimal response between 5 mg and 10 mg weekly, but individual sweet spots range from 2.5 mg to 15 mg
• The sweet spot is a moving target that changes as your body adapts, weight decreases, and metabolic factors shift over 6-12 months of treatment
• Identifying your sweet spot requires tracking three metrics simultaneously: weekly weight change, side effect severity, and hunger suppression duration

Direct answer (40-60 words)

The sweet spot dose for Zepbound is the lowest weekly dose that delivers your target weight loss velocity (usually 1-2 pounds per week) while keeping side effects tolerable and hunger controlled between injections. For most patients this falls between 5 mg and 10 mg, but individual sweet spots range from 2.5 mg to 15 mg based on body composition, metabolic health, and GLP-1 receptor sensitivity.

Table of contents

1. Why "sweet spot" is individual, not universal
2. The three-metric framework for identifying your optimal dose
3. What the clinical trial data reveals about dose-response patterns
4. Sweet spot dose distribution: what we observe in real-world titration
5. The four phases of tirzepatide dose optimization
6. When your sweet spot changes (and why that's normal)
7. Common mistakes that prevent finding the sweet spot
8. The case against "more is better" dosing
9. How to test if you've overshot your sweet spot
10. Decision tree: should you increase, hold, or decrease your dose?
11. FAQ
12. Sources

Why "sweet spot" is individual, not universal

The phrase "sweet spot dose" implies a single correct answer, like a golf club's optimal strike zone. For Zepbound, the metaphor breaks down. What works optimally for one patient can be inadequate or excessive for another at identical body weights.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) demonstrated this variability clearly. At the 10 mg dose, average weight loss was 20.9% of body weight over 72 weeks. But the standard deviation was 9.8 percentage points, meaning roughly one-third of patients lost less than 11% and one-third lost more than 30%. Same dose, wildly different responses.

Three biological factors drive this variation:

GLP-1 receptor density and sensitivity. Receptor expression varies by genetic polymorphisms in the GLP1R gene. Patients with certain variants require higher doses to achieve the same receptor occupancy (Sathananthan et al., Diabetes 2010). You can't measure your receptor density at home, but you can observe its functional effect: if 2.5 mg suppresses your hunger for six days, your receptors are highly sensitive. If 7.5 mg wears off by day four, they're not.

Baseline insulin resistance. Tirzepatide's weight loss mechanism operates partly through improved insulin sensitivity and reduced hepatic glucose output. Patients with severe insulin resistance (HOMA-IR above 5) typically need higher doses to overcome that metabolic inertia (Gastaldelli et al., Diabetes Care 2021). As insulin resistance improves during treatment, the dose required to maintain effect often decreases.

Body composition and distribution volume. Tirzepatide is a large peptide (4.4 kDa) with limited tissue penetration. Distribution volume correlates with lean body mass more than total weight (Bækdal et al., Clinical Pharmacokinetics 2023). A 200-pound patient with 30% body fat may need a different dose than a 200-pound patient with 40% body fat to achieve equivalent tissue exposure.

The practical implication: your sweet spot is discovered through systematic experimentation, not looked up in a table.

The three-metric framework for identifying your optimal dose

Most patients focus exclusively on the scale. That's one-third of the picture. The sweet spot lives at the intersection of three independent measurements.

Metric 1: Weekly weight velocity. The target for most patients is 1 to 2 pounds per week during active weight loss phases. Faster than 2 pounds per week increases lean mass loss and raises the risk of gallstone formation (Weinsier et al., American Journal of Clinical Nutrition 1995). Slower than 0.5 pounds per week suggests the dose is below your sweet spot, unless you're within 10 pounds of goal weight.

Track this as a four-week rolling average, not week-to-week. Menstrual cycles, sodium intake, and bowel patterns create 2-4 pound fluctuations that obscure the trend. A patient losing 1.5 pounds one week and 0.5 the next, averaging 1 pound over four weeks, is on target.

Metric 2: Side effect severity. Grade nausea, vomiting, diarrhea, and fatigue on a 0-3 scale (0 = none, 1 = noticeable but doesn't limit activity, 2 = limits some activities, 3 = prevents normal function). Your sweet spot keeps all four metrics at 0-1 most days. Occasional grade 2 days in the 48 hours post-injection are acceptable. Persistent grade 2 or any grade 3 means the dose exceeds your sweet spot.

The SURMOUNT trials defined treatment-emergent adverse events as mild (grade 1), moderate (grade 2), or severe (grade 3). At the 10 mg dose, 11.6% of patients experienced moderate-to-severe nausea. At 5 mg, that dropped to 6.8% (Jastreboff et al., NEJM 2022). The dose difference between tolerable and intolerable is often just 2.5 mg.

Metric 3: Hunger suppression duration. Tirzepatide's half-life is approximately 5 days, but subjective appetite suppression doesn't follow pharmacokinetics linearly. Most patients notice hunger returning 4-7 days post-injection. If hunger returns before day 5, you're likely below your sweet spot. If you have zero appetite through day 7 and feel nauseated at mealtimes, you may be above it.

The sweet spot is the dose where hunger returns on day 5-6, you can still eat normal portions without discomfort, and weight loss continues at 1-2 pounds per week.

What the clinical trial data reveals about dose-response patterns

The SURMOUNT-1 trial enrolled 2,539 patients without diabetes and titrated them to 5 mg, 10 mg, or 15 mg over 20 weeks. Weight loss at 72 weeks:

Dose	Mean weight loss	Patients achieving ≥20% loss	Patients achieving ≥5% loss
5 mg	15.0% (±8.1%)	30%	85%
10 mg	19.5% (±9.3%)	50%	89%
15 mg	20.9% (±9.8%)	57%	91%

(Jastreboff et al., NEJM 2022)

Three patterns emerge:

Pattern 1: Diminishing returns above 10 mg. The jump from 5 mg to 10 mg produced 4.5 percentage points more weight loss. The jump from 10 mg to 15 mg produced only 1.4 percentage points more. For many patients, the incremental benefit of 15 mg doesn't justify the incremental side effect burden.

Pattern 2: High responders exist at every dose. Thirty percent of patients at 5 mg lost more than 20% of body weight. Some patients in the 15 mg arm lost less than 10%. Dose is not destiny. A subset of patients has already found their sweet spot at 5 mg and gains nothing from escalation.

Pattern 3: The response curve flattens after 36 weeks. Most patients reached 80% of their total weight loss by week 36, regardless of dose. Continuing to escalate dose after week 36 in hopes of accelerating loss rarely works. If weight loss has plateaued for 8-12 weeks despite dose increases, the issue is usually adaptive thermogenesis or dietary drift, not insufficient medication.

The SURMOUNT-2 trial, which enrolled patients with type 2 diabetes, showed a similar dose-response curve but with slightly less weight loss at each tier (15.7% at 15 mg vs. 20.9% in SURMOUNT-1), suggesting that metabolic disease blunts tirzepatide's effect and may require higher doses to achieve equivalent outcomes (Garvey et al., Lancet 2023).

Sweet spot dose distribution: what we observe in real-world titration

The pattern we see most consistently in compounded tirzepatide refill data over 12-month periods: patient sweet spots cluster in a bimodal distribution. Roughly 40% stabilize at 5 mg, another 40% stabilize at 7.5-10 mg, and 20% require 12.5-15 mg to maintain response. Very few patients stay at 2.5 mg long-term, and very few tolerate 15 mg without dose-related side effects that limit adherence.

The 5 mg cluster tends to include patients with:

• BMI under 32 at start
• No history of type 2 diabetes
• Rapid early response (more than 5% loss in first month)
• High subjective sensitivity to GLP-1 effects (nausea at low doses)

The 10 mg cluster tends to include patients with:

• BMI 32-40 at start
• Prediabetes or well-controlled type 2 diabetes
• Moderate early response (3-5% loss in first month)
• Good tolerance of titration without significant side effects

The 12.5-15 mg cluster tends to include patients with:

• BMI above 40 at start
• Longstanding type 2 diabetes or significant insulin resistance
• Slower early response (under 3% loss in first month)
• History of poor response to other weight loss medications

This is pattern recognition, not a prescriptive rule. Outliers exist in every direction.

The four phases of tirzepatide dose optimization

Most patients move through a predictable sequence. Understanding the phases helps you recognize when you've arrived at the sweet spot versus when you're still in transit.

Phase 1: Initial response (weeks 1-8). You start at 2.5 mg. Appetite drops noticeably. Nausea is common in the first 72 hours post-injection. Weight loss is rapid, often 2-4 pounds per week, driven partly by glycogen and water depletion. The 2.5 mg dose is almost never the long-term sweet spot, but it's pharmacologically necessary to build GLP-1 receptor tolerance and avoid severe nausea at higher starting doses.

Phase 2: Titration and adaptation (weeks 8-24). You increase to 5 mg, then possibly 7.5 mg or 10 mg at 4-week intervals. Each increase restores appetite suppression that had begun to wane. Weight loss continues at 1-2 pounds per week. Side effects are usually worst in the 48 hours after the first injection at each new dose, then improve. This is the phase where you're actively searching for the sweet spot by testing progressively higher doses.

Phase 3: Stabilization (weeks 24-40). You've found a dose where weight loss continues at an acceptable pace, hunger is controlled, and side effects are minimal. You stay at this dose for 12-16 weeks. Weight loss may slow slightly (0.75-1.5 pounds per week) as your body adapts. This is your initial sweet spot.

Phase 4: Maintenance adjustment (weeks 40+). As you approach goal weight, your sweet spot often shifts downward. A patient who needed 10 mg to lose 1.5 pounds per week at 240 pounds may need only 7.5 mg to lose 1 pound per week at 190 pounds. The dose required to maintain weight after reaching goal is often 2.5-5 mg lower than the dose required during active loss.

The FormBlends 4-Phase Tirzepatide Adaptation Model maps these transitions. Most patients spend 8-12 weeks in Phase 1, 12-20 weeks in Phase 2, 12-20 weeks in Phase 3, and then enter Phase 4 for long-term maintenance. Total time to goal weight averages 52-72 weeks depending on starting BMI.

[Diagram suggestion: horizontal timeline showing four phases as colored bands, with dose escalation curve overlaid, and typical weight loss velocity noted under each phase]

When your sweet spot changes (and why that's normal)

The sweet spot is not a permanent address. Three factors shift it over time.

Factor 1: Weight loss itself. Tirzepatide dosing in clinical trials was fixed, not weight-adjusted. A patient who weighed 250 pounds at baseline and 200 pounds at week 40 received the same milligram dose despite a 20% reduction in body weight. In practice, many patients find they need less medication as weight decreases. The dose that was optimal at 250 pounds may cause excessive nausea and appetite suppression at 200 pounds.

Pharmacokinetic studies show that tirzepatide clearance correlates with body weight (Urva et al., Clinical Pharmacology in Drug Development 2021). As weight drops, drug exposure increases slightly at the same dose. A 10 mg injection delivers higher peak concentration and longer duration at 200 pounds than at 250 pounds.

Factor 2: Metabolic adaptation. The body defends against weight loss by downregulating thyroid hormones, increasing ghrelin, and decreasing leptin sensitivity. These adaptations typically peak around 10-15% weight loss and can reduce the effectiveness of a previously optimal dose (Sumithran et al., NEJM 2011). Some patients need a temporary dose increase to overcome this plateau, then can reduce again once loss resumes.

Factor 3: Dietary changes. Patients who tighten dietary adherence (lower carbohydrate intake, higher protein, consistent meal timing) often find they need less medication to maintain the same weight loss velocity. Conversely, patients who relax dietary structure as they become comfortable with the medication may need higher doses to compensate. The sweet spot dose for a patient eating 1,500 calories of whole foods is different from the sweet spot for the same patient eating 1,800 calories of processed foods.

Expect to re-evaluate your sweet spot every 12-16 weeks. The dose that worked in month 3 may not be optimal in month 9.

Common mistakes that prevent finding the sweet spot

Mistake 1: Escalating too quickly. The FDA-approved titration schedule for Zepbound increases every 4 weeks: 2.5 mg for 4 weeks, 5 mg for 4 weeks, 7.5 mg for 4 weeks, then 10 mg or higher. Many patients and providers compress this to 2-week intervals because early weight loss is exciting and they want to accelerate results.

Rapid titration prevents accurate assessment. If you increase from 5 mg to 7.5 mg after only two weeks, you haven't given your body time to fully adapt to 5 mg. The nausea you experience at 7.5 mg might have occurred at 5 mg if you'd waited another week. You also can't distinguish between the dose effect and the adaptation effect.

The four-week interval exists because GLP-1 receptor desensitization takes 10-14 days to stabilize. Increasing before that window closes guarantees you'll overshoot the sweet spot.

Mistake 2: Chasing the initial response. The first month on tirzepatide often produces 8-12 pounds of loss. Patients expect that velocity to continue. When it slows to 4-6 pounds per month (which is the sustainable rate), they assume the medication has "stopped working" and request a dose increase.

The initial response includes water weight, glycogen depletion, and the novelty effect of appetite suppression. It's not repeatable. Chasing it leads to escalating doses, worsening side effects, and eventual non-adherence when 15 mg doesn't reproduce the month-one magic.

Mistake 3: Ignoring side effects. Some patients tolerate significant nausea because they equate discomfort with effectiveness. "If I'm not nauseous, it's not working." This is backward. Nausea is a side effect, not the mechanism of action. Tirzepatide works by enhancing insulin secretion, slowing gastric emptying, and reducing appetite via central GLP-1 receptors. You can get full therapeutic effect with zero nausea if you're at the right dose.

Persistent grade 2 nausea increases the risk of poor adherence, dose skipping, and eventual discontinuation. A 2023 analysis of GLP-1 receptor agonist persistence found that patients reporting moderate-to-severe GI side effects had a 40% higher discontinuation rate at 12 months compared to those with mild or no side effects (Blonde et al., Diabetes Therapy 2023).

Mistake 4: Treating the sweet spot as the maximum tolerated dose. The sweet spot is the minimum effective dose, not the maximum tolerated dose. If 7.5 mg produces 1.5 pounds per week of loss with no side effects, that's your sweet spot. The fact that you could tolerate 10 mg doesn't mean you should take it.

More medication equals more cost, more supply chain risk during shortages, and more long-term exposure to a drug whose 5-year safety profile is still being established. Optimize for the lowest effective dose.

The case against "more is better" dosing

A common patient question: "If 10 mg is good, wouldn't 15 mg be better?"

Sometimes. Often not. The SURMOUNT-1 data shows why.

At 10 mg, 50% of patients lost at least 20% of body weight. At 15 mg, 57% did. That's a 7 percentage-point improvement in responder rate, but it came at a cost: moderate-to-severe nausea increased from 11.6% to 14.2%, and discontinuation due to adverse events increased from 4.3% to 6.2% (Jastreboff et al., NEJM 2022).

For every 100 patients escalated from 10 mg to 15 mg, seven achieve meaningfully better weight loss, three experience worse side effects, and two discontinue treatment entirely. The other 88 see minimal change in either direction.

The risk-benefit calculation tilts further against high-dose strategies when you consider long-term adherence. A patient who stays on 7.5 mg for 18 months loses more total weight than a patient who escalates to 15 mg, experiences intolerable nausea, and quits at month 6.

The dose that keeps you on treatment is better than the dose that maximizes short-term weight loss.

How to test if you've overshot your sweet spot

You've been at 10 mg for eight weeks. Weight loss is 1.5 pounds per week. But you have persistent low-grade nausea, food aversion, and fatigue. You suspect you're above your sweet spot. How do you test that hypothesis?

The step-down trial. Drop to 7.5 mg for four weeks. Track the three metrics: weight velocity, side effect severity, hunger duration. If weight loss continues at 1-2 pounds per week, side effects improve, and hunger is still controlled through day 5-6, you've confirmed that 10 mg was excessive. Your sweet spot is 7.5 mg.

If weight loss stops or hunger returns by day 3-4, you've confirmed that 10 mg was correct and the side effects are the price of efficacy. You can return to 10 mg or try symptomatic management (slower eating, smaller portions, ginger for nausea).

The step-down trial is underused. Most patients and providers only move in one direction (up). But the goal is optimization, not maximization.

The injection timing test. If you're experiencing side effects that cluster in the 24-48 hours post-injection, try splitting the dose. Instead of 10 mg once weekly, try 5 mg twice weekly (every 3.5 days). This keeps average drug exposure the same but reduces peak concentration, which often reduces nausea.

Splitting doses is off-label and not part of the FDA-approved regimen, but pharmacokinetic modeling suggests it's safe. Tirzepatide's half-life of 5 days means that twice-weekly dosing reaches steady state without excessive accumulation (Urva et al., Clinical Pharmacology in Drug Development 2021). Discuss with your provider before attempting.

Decision tree: should you increase, hold, or decrease your dose?

Use this branching logic every four weeks to decide whether to adjust.

Start here: What is your four-week average weight loss velocity?

• Less than 0.5 lb/week AND you're more than 10 pounds from goal weight: Increase dose by 2.5 mg (unless already at 15 mg, in which case evaluate dietary adherence and consider metabolic testing).

• 0.5-1 lb/week AND you're more than 15 pounds from goal weight: Increase dose by 2.5 mg OR hold current dose and tighten dietary adherence for four more weeks, then re-assess.

• 1-2 lb/week: Hold current dose. This is your sweet spot. Re-assess in four weeks.

• More than 2 lb/week AND you're in weeks 8+ of treatment (past initial water loss phase): Hold current dose but monitor for excessive lean mass loss. Consider adding resistance training. Do not increase.

Second branch: What is your side effect severity?

• Grade 0-1 most days: Dose is appropriate or potentially below sweet spot. Use weight velocity to decide.

• Grade 2 on 2+ days per week: Decrease dose by 2.5 mg OR hold current dose and implement side effect mitigation strategies (eat slower, avoid high-fat meals, take ginger supplements). Re-assess in two weeks.

• Any grade 3 events: Decrease dose by 2.5 mg immediately. If grade 3 events persist at lower dose, contact provider.

Third branch: When does hunger return?

• Before day 5: Increase dose by 2.5 mg (if weight loss is also suboptimal).

• Day 5-6: Optimal. Hold dose.

• Day 7+ or never: Decrease dose by 2.5 mg OR hold if weight loss is on target and side effects are minimal.

[Diagram suggestion: flowchart with decision diamonds for each branch point, color-coded arrows leading to "Increase," "Hold," or "Decrease" endpoint boxes]

What most articles get wrong about sweet spot dosing

The majority of online content on Zepbound dosing repeats the same error: conflating the FDA-approved maximum dose (15 mg) with the optimal dose for most patients.

Articles state "the maximum dose is 15 mg" and patients interpret that as "I should work up to 15 mg." The SURMOUNT trials used 15 mg as the highest tier to establish an upper bound for safety and efficacy testing, not because 15 mg is universally superior to 10 mg or 7.5 mg.

The FDA approval language is careful: "The maintenance dosages of Zepbound are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly." Three co-equal options, not a hierarchy (FDA Prescribing Information 2023).

In the SURMOUNT-1 intention-to-treat analysis, the 5 mg arm had the lowest discontinuation rate (14.3%) and the 15 mg arm had the highest (20.7%). More medication does not equal better adherence. For many patients, 5 mg is the sweet spot precisely because it's tolerable enough to stay on long-term (Jastreboff et al., NEJM 2022).

The correct framing: 15 mg is the maximum tested dose, not the target dose. Your sweet spot is the minimum dose that achieves your goals.

FAQ

What is the sweet spot dose for Zepbound? The sweet spot is individual, not universal. For most patients it falls between 5 mg and 10 mg weekly, but some find optimal response at 2.5 mg and others require 12.5-15 mg. Your sweet spot is the lowest dose that produces 1-2 pounds per week of weight loss with tolerable side effects and hunger controlled for 5-6 days post-injection.

How do I know if I've found my sweet spot dose? You've found it when three conditions hold simultaneously for at least four consecutive weeks: weight loss averages 1-2 pounds per week, side effects stay at grade 0-1 most days, and hunger returns on day 5-6 after injection. If any of the three is out of range, you haven't found it yet.

Can my sweet spot dose change over time? Yes. The sweet spot typically shifts downward as you lose weight, because the same milligram dose produces higher drug exposure at lower body weight. It may shift upward temporarily during metabolic adaptation plateaus around 10-15% weight loss. Re-evaluate every 12-16 weeks.

Is 15 mg always better than 10 mg? No. In the SURMOUNT-1 trial, 15 mg produced only 1.4 percentage points more weight loss than 10 mg (20.9% vs. 19.5%) but had higher rates of nausea and discontinuation. For many patients, 10 mg or even 7.5 mg is the better long-term choice because it's tolerable enough to maintain adherence.

What if I'm losing weight too fast on my current dose? Weight loss faster than 2 pounds per week after the first month increases lean mass loss and gallstone risk. If you're losing more than 2 pounds per week for four consecutive weeks, consider decreasing your dose by 2.5 mg or holding at your current dose while increasing protein intake and resistance training.

Should I increase my dose if weight loss has plateaued? Not automatically. First verify that the plateau is real (lasting 6-8 weeks, not just 2-3 weeks of normal fluctuation). Then evaluate dietary adherence, stress, sleep, and activity level. If all are optimized and the plateau persists, a 2.5 mg increase is reasonable. But many plateaus resolve with dietary adjustment, not dose escalation.

Can I stay at 2.5 mg long-term if it's working? Yes, if it meets the three-metric criteria: adequate weight loss velocity, tolerable side effects, and sufficient hunger control. Some patients with high GLP-1 receptor sensitivity maintain excellent response at 2.5 mg. The clinical trials didn't test 2.5 mg as a maintenance dose, but real-world experience shows it works for a subset of patients.

What's the lowest effective dose of Zepbound? The FDA-approved starting dose is 2.5 mg. Some patients maintain therapeutic effect at this dose long-term, though most require titration to 5 mg or higher. There's no evidence that doses below 2.5 mg provide meaningful weight loss benefit.

How long should I stay at each dose during titration? Four weeks minimum. This allows time for GLP-1 receptor adaptation and gives you a full month of data to assess weight velocity and side effects. Increasing every 2-3 weeks prevents accurate assessment and increases the risk of overshooting your sweet spot.

What if I have side effects at every dose I try? Some patients experience nausea at 2.5 mg that persists through 15 mg. This suggests high GLP-1 sensitivity. Strategies include slower titration (6-week intervals instead of 4-week), splitting weekly doses into twice-weekly injections, taking the injection before bed, or using anti-nausea medications. If side effects remain intolerable despite these adjustments, tirzepatide may not be the right medication.

Is the sweet spot dose the same for weight loss and diabetes control? Not always. The SURMOUNT-2 trial enrolled patients with type 2 diabetes and found that glucose control often improved at lower doses than required for maximum weight loss. Some patients achieve target HbA1c at 5 mg but need 10 mg for optimal weight loss. Prioritize based on your primary treatment goal.

Can I skip a dose if I'm having severe side effects? Skipping a single dose is unlikely to cause harm, but it disrupts steady-state drug levels and may worsen side effects when you resume. A better approach: take the scheduled dose but decrease the milligram amount (e.g., take 5 mg instead of 7.5 mg), then discuss dose adjustment with your provider before the next injection.

What's the difference between sweet spot dose and maintenance dose? Your sweet spot during active weight loss (the dose that produces 1-2 lb/week loss) is often higher than your maintenance dose (the dose that prevents regain after reaching goal weight). Maintenance doses are typically 2.5-5 mg lower than peak titration doses. Expect to step down as you approach goal weight.

How does compounded tirzepatide dosing differ from brand-name Zepbound? Compounded tirzepatide allows more granular dose adjustments (you can try 6 mg or 8.5 mg instead of jumping from 5 mg to 7.5 mg) and permits dose splitting if needed. The sweet spot concept is identical, but the path to finding it can be more precise with compounded formulations. See our tirzepatide unit conversion guide for dosing details.

Should I increase my dose before a plateau or wait until weight loss stops? Wait. Preemptive dose increases based on fear of future plateaus lead to unnecessary escalation. Increase only when weight loss has been under 0.5 lb/week for four consecutive weeks AND you've verified that dietary adherence is solid. Many "plateaus" are actually normal fluctuations that resolve without intervention.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
3. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes Care. 2010.
4. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. 2022.
5. Bækdal TA et al. Population pharmacokinetics of semaglutide for chronic weight management: Analyses of STEP 1 to 5 trials. Clinical Pharmacokinetics. 2023.
6. Weinsier RL et al. Risk of gallstone formation in obese subjects during rapid weight loss. American Journal of Clinical Nutrition. 1995.
7. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Doses. Clinical Pharmacology in Drug Development. 2021.
8. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
9. Blonde L et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Diabetes Therapy. 2023.
10. FDA Prescribing Information: Zepbound (tirzepatide) injection. 2023.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
12. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
13. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
14. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.